-
Who we are
Who we are
Novavax is a global biotechnology company with a proven vaccine technology. We are focused on developing our R&D assets and establishing partnerships to leverage the value of our technology to help protect health.
Discover our scienceLearn about our validated protein-based nanoparticle and Matrix-M™ adjuvant technology.
-
What we do
What we do
Novavax is focused on using our proven vaccine technology to help protect health through the development of our R&D assets and establishing partnerships
Latest UpdatesStay current with Novavax news as we make progress in discovering and developing innovative vaccines to help protect against serious infectious diseases.
-
Blog
Blog
Novavax is committed to accelerating the development of new and promising vaccines and sharing information based on years of study and experience.
Who we are

Novavax is a global biotechnology company focusing on driving value via our proven recombinant nanoparticle and Matrix-M™ technology through partnerships and R&D. To do this, we are focused on four value drivers: executing on current partnerships, developing our late-stage assets, driving additional partnerships and deals through our technology, and building a robust early-stage pipeline.
Our mission
By leveraging our science, our technology and our people, we will innovate and collaborate to tackle the world's most significant health challenges
Our vision
We envision a world where our technology is amplified to touch the lives of billions, sparking transformation in global health

Our leadership
Our team has unparalleled experience developing vaccines, conducting early proof-of-concept and clinical development work, and executing successful partnerships for further development and commercialization. Their immense depth of experience is ideally suited to exponentially increase the public health impact of our recombinant protein-based nanoparticle and Matrix-M™ adjuvant technology, while driving value for the Company.

Our partners
We seek and encourage meaningful partnerships and collaborations with leading pharmaceutical and biopharmaceutical organizations, research institutions, government agencies and foundations to further the impact of our proven technology

The power & speed of nanoparticle technology
Our vaccine technology combines power and speed with the immunogenicity-enhancing properties of our Matrix-M™ adjuvant to efficiently produce highly immunogenic particles targeting some of the most pressing viral infectious diseases.

Our pipeline is more important than ever
Novavax has demonstrated its ability to produce viable, promising vaccine candidates for emerging infectious diseases.

Our commitments
As a global leader in vaccine development and research, we hold our commitments and honor our responsibilities with the goal of improving global health.
